# US 2012/0237473 A1 · Compositions And Methods For Cell Based Retinal Therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0237473 A1
- Document ID: US20120237473A1
- Status: Published application
- Kind: A1
- Application number: 13/420,502
- Filed: 2012-03-14
- Published: 2012-09-20
- Earliest claimed: 2011-03-14
- Assignees: University of Medicine and Dentistry of New Jersey
- Inventors: Anton Kolomeyer; Ilene Sugino; Marco Zarbin
- Web page: https://patentgrep.com/patent/US20120237473A1

## CPC

- C12N 5/062: {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- C12N 2502/085: eye cells
- G01N 2333/71: for growth factors; for growth regulators
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation.

## Claims

### Claim 1

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and at least two biologically active trophic factors selected from the group consisting of LIF, bFGF, HB-EGF, VEGF-A, NGF, BDNF, CNTF, PEDF, IGFBP-3, isoform 1 of semaphoring-3B, TGF-β and HGF.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein, the selected biologically active trophic factors are HGF and PEDF.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1 comprising LIF, bFGF, HB-EGF, VEGF-A, NGF, BDNF, CNTF, HGF and PEDF.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutically acceptable carrier is capable of sustained release delivery of said factors.

### Claim 5 (depends on 1)

A method to decrease the degeneration of a retina associated with an ocular condition in a subject in need thereof comprising administration to said subject an effective amount of the pharmaceutical composition of claim 1.

### Claim 6 (depends on 5)

The method of claim 5, wherein the pharmaceutical composition is administered by intraocular administration.

### Claim 7 (depends on 5)

The method of claim 5, wherein said ocular condition is selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, glaucoma, optic atrophy, ocular inflammation, retinopathy, diabetic retinopathy, retinal ganglion cell dysfunction, and retinal detachment.

### Claim 8

A method to select a group of cells that secrete factors that decrease the degeneration of a retina comprising:
a. isolating medium from a group of cultured cells;
b. culturing a degenerating animal retina with said isolated medium;
c. determining the degeneration of the retina; and
d. comparing the level of the degeneration of the retina to a standard;
wherein the group of cells are selected if said isolated medium decreased the degeneration of the retina compared to the standard.

### Claim 9 (depends on 8)

The method of claim 8, where in the group of cells are stem cells capable of differentiating to retinal pigment epithelial cells, or fetal retinal pigment epithelial cells.

### Claim 10 (depends on 8)

The method of claim 8, wherein the determining step is conducted by performing a cytotoxicity assay and/or an apoptotic assay.

### Claim 11 (depends on 8)

The method of claim 8, wherein the standard is the level of the degeneration of a retina cultured in non-conditioned medium.

### Claim 12 (depends on 8)

The method of claim 8, wherein the cells are human cells

### Claim 13 (depends on 8)

The method of claim 8, wherein the group of cultured cells is cultured in a solid support.

### Claim 14 (depends on 8)

The method of claim 8, wherein the degenerating retina is cultured in a solid support.

### Claim 15 (depends on 8)

The method of claim 8, wherein the animal retina is a human retina or a porcine retina.

### Claim 16

Conditioned medium isolated from fetal retinal pigment epithelial cells cultured in medium in a solid support, wherein said medium is isolated after said cells have been passaged from 2 to 6 passages and within 7 days of said passage.

### Claim 17

A method of identifying cells for transplantation to a subject having an ocular condition comprising:
a. isolating medium from a group of cultured cells;
b. culturing a degenerating animal retina with said isolated medium;
c. determining the degeneration of the retina; and
d. comparing the level of the degeneration of the retina to a standard;
wherein the group of cells are selected if said isolated medium decreased the degeneration of the retina compared to a standard.

### Claim 18 (depends on 17)

The method of claim 17, wherein said group of cells are stem cells isolated from the subject.

### Claim 19 (depends on 17)

The method of claim 17, wherein the cells are human cells

### Claim 20 (depends on 17)

The method of claim 17 wherein the group of cultured cells is cultured in a solid support.

### Claim 21 (depends on 17)

The method of claim 17 wherein the degenerating retina is cultured in a solid support.

### Claim 22 (depends on 17)

The method of claim 17 wherein the animal retina is a human retina or a porcine retina.

### Claim 23

A kit for identifying an agent that decreases degeneration of a retina wherein the kit comprises an explant culture of full thickness animal retina.

### Claim 24 (depends on 23)

The kit of claim 23 wherein the retina is a human or a porcine retina.

### Claim 25 (depends on 23)

The kit of claim 23 further comprising reagents for performing an assay for measuring retinal degradation.
